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Background: Chronic lymphocytic leukemia (CLL) is a mature B-cell neoplasm characterized by the expansion of
CD5-positive lymphocytes in peripheral blood. While CLL is the most common type of leukemia in Western
populations, the disease is rare in Africans. Hence, clinical and laboratory data and studies of CLL in Sub Saharan
populations have been limited. The aims of this study were to analyze the characteristics of senegalese patients
with CLL at the time of the diagnosis and to identify the correlation between clinical characteristics (Binet stage)
with age, gender, laboratory parameters and chromosomal abnormalities.
Methods: In this study, we investigated the clinical and laboratory characteristics of CLL in Senegal. A total of 40
patients who had been diagnosed with CLL during the period from July 2011 to April 2015 in Senegal were
evaluated. Cytology and immunophenotype were performed in all patients to confirm the diagnosis. The prognosis
factors such as Binet staging, CD38 and cytogenetic abnormalities were studied. The statistical analysis was
performed using STATA version 13 (Stata college station Texas). Each patient signed a free and informed consent
form before participating in the study.
Results: The mean age was 61 years ranged from 48 to 85. There were 31 males and only 9 females (sex ratio M :
F = 3,44). At diagnosic, 82.5 % of the patients were classified as having advanced Binet stages B or C. The prognosis
marker CD38 was positive in 28 patients. Cytogenetic abnormalities studied by FISH were performed in 25 patients,
among them, 68 % (17 cases) had at least one cytogenetic abnormality and 28 % had 2 simultaneous cytogenetic
abnormalities.
Conclusion: Africans may present with CLL at a younger age and our data suggest that CLL in Senegal may be
more aggressive than in Western populations.
Keywords: Chronic lymphocytic leukemia, Clinic, Cytology, Immunophenotype, Cytogenetic abnormalitiesBackground
Chronic lymphocytic leukemia (CLL) is the most frequent
form of leukemia in Western countries [1, 2]. The median
age at diagnosis ranges between 67 and 72 years and males
are more likely to develop the disease than females [3, 4].
CLL is characterized by clonal proliferation and accumula-
tion of mature, typically CD5-positive B-cells within the
blood, bone marrow, lymph nodes, and spleen [5]. It is a
heterogeneous disease which can present as an aggressive
and life threatening leukemia or as an indolent form that* Correspondence: sallabibatou@gmail.com
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[6] and Binet et al. (1981) [7] staging systems are the
standard clinical staging to estimate prognosis of patients.
However, both systems fail to indicate the higher risk of
progression among patients in early stages of the disease.
These clinical staging systems were complemented by
prognostic markers based on : serum prognostic factors,
immunoglobulin heavy chain variable region (IGHV)
mutation status, some cytogenetic abnormalities, cell
membrane expression of CD38, and intracellular expres-
sion of zeta-associated protein-70 (ZAP- 70) [5, 8, 9].
As CLL is a rare disease in Africa [10, 11], clinical and
laboratory data and studies in Sub Saharan populationsistributed under the terms of the Creative Commons Attribution 4.0
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we have investigated the clinico-biological characteristics
of the disease at time of diagnosis.
The first objective of this current study was to analyze
the characteristics of senegalese patients with CLL at the
time of the diagnosis. The second objective was to identify
the correlation between clinical characteristics (Binet stage)




In a prospective study, a total of 40 patients diagnosed
with CLL between July 2011 to April 2015, in different
hospitals in Senegal were evaluated. The diagnosis was
based on morphological and immunophenotypical find-
ings according the World Health Organization (WHO)
classification (2008) [12]. The patients were not treated
at diagnosis and clinical characteristics including age,
gender, symptoms and clinical features were provided by
referring physicians. All of the patients were classified
using the Binet staging system as one of the three
groups (A, B or C). The Binet staging system [7] is based
on the number of involved areas, as defined by the pres-
ence of enlarged lymph nodes of greater than 1 cm in
diameter or organomegaly, and on whether there is
anemia or thrombocytopenia. Binet stages are defined as
follows:
 Stage A : Hemoglobin (Hb) more than 10 g/dL and
platelets above 100 x 109/L and to two of the
superfical lymph nodes involved.
 Stage B : Hb above 10 g/dl and platelets above 100 x
109/L and organomegaly greater than that defined
for Stage A (i.e., three or more areas of nodal or
organ enlargement).
 Stage C : All patients who have Hb of less than
10 g/dL and/or a platelet count of less than 100 x
109/L, irrespective of organomegaly.
Peripheral Blood cells Counts
The peripheral blood cells counts were performed on
the Symex XT2000i TM (Sysmex Diagnostics, Japan) and
a blood smear stained by May Grunwald Giemsa was
obtained for all patients.
Immunophenotypical analysis
In each patient, immunophenotype of leukemic cells was
performed by flow cytometry, using the FacsCalibur™ flow
cytometer (Becton Dickinson, CA, USA). Different panels
of antibodies were used to assess the immunophenotype
CLL scoring system proposed by Matutes et al. [13]. These
monoclonal antibodies were : CD45-APC/CD19-PerCP/
kappa-FITC/lambda-PE/CD5-PE/FMC7-FITC/CD22-FITC/CD23-PE/CD10-FITC/CD38-PE/CD11c-PE/CD25-FITC/
CD103-FITC. Data were acquired and analyzed with the
BD CellQuest Pro software (Becton Dickinson).
Fluorescence in situ hybridization
Cytogenetic abnormalities were determined by Fluores-
cence in situ hybridization (FISH) on peripheral blood
using Vysis probes (Abbott) according to the manufac-
turer recommandations. The following abnormalities :
del13q14 (D13S319 probe), del 11q22 (ATM probe),
del17p13 (TP53 probe) and trisomy 12 (CEP 12 DNA
Probe) were tested.
Ethical considerations
The study was approved by the « Research Ethics Com-
mittee » of Cheikh Anta Diop University and each patient
signed a free and informed consent form before participat-
ing. A written consent for publication of personal infor-
mation, such as that contained in table, was obtained from
all participants. Written consent to publish the images
contained in Fig. 1 was also obtained from the relevant
participant.
Statistical analysis
Data were collected using Microsoft Excel Spreadsheet
and then transferred to Stata for data management and
statistical analysis. Continuous variables were described
as mean with standard deviation or as median with inter
quartile range if the variable was not normally distrib-
uted. Qualitative variables were described as proportion.
For the bivariate analysis, difference between means was
tested using the student t-test or the Mann–Whitney
non-parametric depending on the normality assumption.
Association between categorical variables was performed
using the Pearson chi-square test or the Fisher exact test.
The estimations were done within a 95 % confidence level
and the entire statistical tests were significant when the p
value was below the threshold level of 0.05. The statistical
analysis was performed using STATA version 13 (Stata
college station Texas).
Results
Of the 40 patients studied, 31 were males and only 9
females (sex ratio M : F = 3,44). The mean age was
61 years ranged from 48 to 85. Table 1 shows the age
and sex distribution of the CLL patients in this study.
CLL occurred frequently between 55–70 years (55 % of
patients). Just over one quarter of patients was under
50 years old.
The most frequently found symptoms were related to
tumor syndrome; it was mainly discomfort, pain or mass
abodominal observed in 80 % of cases. Signs of impaired
general condition: weight loss, asthenia or anorexia were
Fig. 1 a Bulky cervical lymph nodes. b Huge splenomegaly with splenic abcess. c Peripheral blood smear, typical small lymphocytes,with hypermature
clumped chromatin and scanty cytoplasm. Presence of smudge cells (arrows). d Immunophenotype with CD38 positivity. e FISH, bi allelic deletion of
13q. f trisomy 12 (FISH)
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only one patient with a bleeding symptoms (Table 2).
Clinically, tumor syndrome was evident in most pa-
tients. The enlarged lymph nodes were present in 72 %
of patients (Fig. 1a) and 26 patients had a palpable
spleen of which 40 % had at least one splenomegaly ac-
cording to Hackett type III (Fig. 1b).
The average lymphocytosis was very high : 186.68x109/
L, ranges between : 5.03 to 869x109/L. The blood smears
showed mature lymphocytes with clumped chromatin
and scanty cytoplasm (Fig. 1c). Prolymphocytes, counted
in all cases, were present in only 9 cases and the per-









Female 9 22.5were observed in almost all peripheral blood smears
except in 3 cases.
The mean hemoglobin level was 9.5 g/dl (Ranges: 3.9
to 15.2), 55 % of patients had an hemoglobin less than
10 g/dl. Thrombocytopenia was observed in 21 patients.
The platelets count was below 50x109/L in 6 patients
(patients : 3, 15, 18, 23, 32, 40. Table 3) and the mean
platelets levels was 149.07x109/L (Ranges: 21- 452x109/L)
(Table 3).
At diagnosis, 82.5 % of patients dysplayed an advanced
Binet clinical stage : 22.5 % were stage B and 62.5 %
were stage C. Only 7 patients were in stage A.
The Matutes scoring was 4 or 5 in almost all patients
confirming the CLL diagnosis. Three patients had an
atypical CLL with a score at 3/5.
The prognosis marker CD38 was positive (Fig. 1d) in
28 patients of the series, including 4 patients in stage A
(Table 4).
Cytogenetic abnormalities studied by FISH were per-
formed in 25 patients, among them, 68 % (17 cases) had
at least one cytogenetic abnormality and 28 % had 2
simultaneous cytogenetic abnormalities.
The 13q deletion was found in 44 % of cases (11/25)
and 3 patients (patients 6, 15, 23. Table 3) had a biallelic
deletion (Fig. 1e). Seven patients had trisomy 12 (Fig. 1f )
while 11q and 17p deletions were found in 3 cases each.





Weight loss 21 52.5
Abdominal pain/discomfort 19 47.5
Abdominal mass 13 32.5
Weakness 26 65
Cervical, axillary or inguinal mass 19 47.5
Anorexia 12 30
Fever 07 17.5
Nght swaet 03 7.5
Bleeding 01 2.5
Signs
Anaemia- Pallor 25 62.5
Lymphadenopathy (cervical, axillary, inguinal) 36 72
No lymphadenopathy 04 10
Splenomegaly
- moderate (I, II Hackett) 11 27.5
- gross splenomegaly (III, IV,V Hackett) 16 40
Spleen no palpable 13 32.5
Hepatomegaly 06 15
Respiratory tract infection 04 10
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deletion were in stage C (Table 3). Twenty four percent
of patients on Stage A or B had at least one cytogenetic
abnormality versus 66.7 % in stage C. However this dif-
ference was not statistically significant (p value = 0.23
Table 4). The deletion of the long arm of the chromo-
some 11 were observed in 8.3 % of patients with stage A
or B and in 15, 4 % of patients classified in the advanced
stage (stage C). The statistical test shows that this differ-
ence was not significant (p = 0.58). In addition, the deletion
of the short arm of the chromosome 17 was not observed
in any patient on stage A or B, whereas this abnormality
was detected in 24 % of patients on stage C (Table 4).
The number of lymphocytes count was significantly
greater in patients with stage C than in those in the
group with stages A or B (p = 0.005). The average num-
ber of lymphocytes was 269.5 x 109/L in the advanced
stage group compared to 61.5 x 109/L in patients classi-
fied in stage A or B.
Discussion
Chronic lymphocytic leukaemia (CLL) is the most com-
mon form of leukaemia in Western countries [1, 2] while
it is extremely rare in Africa [10, 11]. In 3 years, only 40
patients with CLL were identified in several centers of
Senegal with an average age of 61 years (Ranges : 48–85years). This average age is comparable to Nigerian
[10, 11] and Ethiopian [14] studies which found respect-
ively a mean age of 60, 56 and 55 years.
However, this average age at diagnosis is somewhat
higher in Western Countries : American (72 years) [5],
English (74 years) [15] or French (72 years) [16]. There is
at least 10 years between the age of onset of CLL in African
compared to Westerners. We speculate that Africans
present with CLL at a younger age than Western patients.
These data may support the idea that environmental
factors, remaining to be identified, may be involved. It
has been postulated that CLL occurring in younger
adults in Africa is a consequence of recurrent malaria
and other infections, resulting in a polyclonal B-cell pro-
liferation which in an extreme form is hyper reactive
malarial splenomegaly [17].
Male dominance has been reported in the most published
series [5, 10, 15, 16]. In ours, male dominance was evident
with a ratio M/F = 3.44. A different evolution according to
gender was however raised and proved [3, 18, 19]. Catovsky
et al. [4] demonstrates that CLL runs a more benign clinical
course in women than in men. Women were more likely to
have Binet stage A than B or C; their overall survival rates
at 10 years were better than for men and they had a better
overall response to treatment. No good hypothesis have
been advanced to explain the observed trend for a better
outcome in women. However, the implications of gender
differences in the pathogenesis of CLL and its treatment re-
quire further studies. Among our 40 cases, 9 were women
(4 in stage A or B and 5 in stage C). We have not however
found significant differences between men and women
compared to Binet stages (p = 0.75).
CD38 is a well-known lymphocyte differentiation anti-
gen with proposed receptor and adhesion molecule
functions. In mature circulating B cells, CD38 ligation
induced proliferation by promoting the expression of
CD25, MHC-II, and certain cytokines [20, 21].
The prognosis role of CD38 in CLL was first proposed
on the basis of an immunophenotypical study of CLL
cases with known IGHV sequences. CD38 predicted
shorter overall survival rates when expressed on 30 % or
more CLL cells [22]. Since this report in 1999, CD38 ex-
pression has been well established as an independent
prognostic factor in CLL by numerous reports, but with
various cut-off levels. While Del Poeta et al. [23] and
Hamblin et al. [24] proposed 30 % as the best cut-off,
others proposed 20 % [25] or even 7 % [26]. Further co-
operative studies are still necessary to define a common
cut-off level. We use the cut-off of 30 % in our patients.
The CD38 were express in 70 % of patients from the
series; 12 of them were stage A or B and 16 patients in
stage C in the Binet system. We did not find significant
difference between the expression of CD38 and the dif-
ferent stages of Binet (p = 0.75).
























1 63/F 33.4 13.3 279 A + - - - -
2 50/F 268.8 8.4 140 C + - - Yes -
3 65/M 52.248 12.4 24 B + Yes - - -
4 53/M 831.14 5.2 69 C + Yes Yes - -
5 54/M 225.5 7.5 137 C Negative Yes - - -
6 69/M 179.5 4.4 81 C + Yes (biallelic) - - -
7 80/M 49 11.2 200 A Negative - - - -
8 63/M 230 9.3 206 C + - - Yes Yes
9 50/M 58 8.8 66 C + - Yes - -
10 51/M 88.55 9.5 97 C + - - - -
11 63/M 145.78 9.7 203 C Negative Yes - - Yes
12 59/M 42.6 10.3 126 B + yes - Yes -
13 67/M 5.8 15.2 220 A + - - - -
14 67/F 6.4 11.6 332 A + Yes - - -
15 70/M 491.4 6 31 C + Yes (biallelic) - Yes -
16 57/F 12.8 13 229 A + - - - -
17 80/F 93.34 13.2 157 B + Yes - Yes -
18 60/M 82.3 7.9 28 C Negative - - Yes -
19 85/M 397 8.9 108 C + - - - Yes
20 54/M 87.8 10.7 239 A Negative - - - -
21 60/M 16.38 12.6 276 B + - - - -
22 63/M 789.2 8 262 C Negative - - - -
23 54/M 51.76 4.9 44 C + Yes (biallelic) - - -
24 67/M 201.5 10.3 263 B + - - yes -
25 60/M 171 12 203 B + yes yes - -
26 72/M 15 6.5 115 C Negative
27 58/M 7.1 12.1 146 A Negative
28 73/M 241 7.6 242 C +
29 74/M 12.7 10.9 157 B Negative
30 63/M 734 8.8 151 C Negative
31 68/M 5.03 12.1 64 C +
32 48/M 165.33 6.7 34 C Negative
33 60/M 85.5 11 152 B +
34 52/M 156.3 11.2 452 B +
35 48/F 365.8 9.7 76 C +
36 78/F 198 7.4 115 C +
37 54/F 27 9.8 88 C +
38 59/M 131 12.8 76 C Negative
39 64/F 869 9 54 C +
40 55/M 114.41 3.9 21 C +
Mean 186.68 9.5 149.07
CD38 expression : positive if >30 %
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Table 4 Correlation between clinical stage and laboratory findings
Characteristics Clinical staging system according to Binet and al.
Either stage A or B Stage C P value*
N (%) N (%)
Age (years) n = 40
<55 2 (12.5) 9(37.5) 0.1
55-70 11 (68.7) 11(45.8)
<70 3 (18.75) 4 (16.67)
Sex (n = 40)
Male 12 (75) 19 (20) 0.75
Female 4 (25) 5 (80)
Average lymphocytes x109/L (n = 40) 61.5 269.5 0.005*
At least one cytogenetic abnormality (n = 25)
Yes 06 (24) 11 (44) 0.097
No 06 (24) 02 (08)
Deletion 13q
Yes 05 (42) 06 (46.15) 0.82
No 07 (58) 07 (53.85)
Deletion 11q
Yes 1 (8.3) 2(15.4) 0.58
No 11 (91.7) 11(84.6)
Trisomy 12
Yes 03 (25) 04 (31) 0.74
No 9 (75) 9 (71)
Deletion 17p
Yes 00 (00) 03 (24) 0.07
No 12 (100) 10 (76)
CD38 expression (n = 40)
Positive 12 (75) 16 (67) 0.75
Negative 04 (25) 08 (33)
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etic abnormalities perfomed by FISH. The 13q deletion
was found in 11 patients (44 %), 6 of them were in stage
C. Deletions on the long arm of chromosome 13, specif-
ically involving band 13q14 (del (13q14)) represent the
single most frequently observed cytogenetic aberration
in CLL, occurring in approx. 55 % of all cases [5]. An
isolated del 13q14 is typically characterized by a benign
course of the disease. Three of our patients had a bialle-
lic deletion of 13q and they were all in Binet stage C.
Nevertheless it has been demonstrated that, there was
no difference in the baseline characteristics between pa-
tients with CLL who had monoallelic or biallelic deletion
of 13q. In addition, there was no significant difference in
endpoints, including time to treatment [27]. Interest-
ingly, it has been shown that the size of the 13q deletion
is associated with outcome, since patients with CLL with
larger aberrations have a shorter time to treatment andoverall survival, indicating that several genes included in
the deletion have an effect on the disease course [28, 29].
Trisomy 12 is detected in 11–16 % of patients at
diagnosis [9] and is associated with an intermediate
prognosis [9, 30, 31]. Seven of our patients had trisomy 12
(28 %) including 4 stage C Binet (p = 0.74). The genes
involved in the pathogenesis of CLL carrying a trisomy 12
are largely unknown. Furthermore, the prognostic rele-
vance of trisomy 12 remains a matter of debate [32].
The deletions of 11q22-q23 and 17p13 are known to
be associated with poor prognosis in CLL [5, 9, 31, 32].
The deletion of 11q is most often monoallelic and car-
ried by 10–17 % of patients with CLL [9, 30]. The min-
imal deleted region is known to encode several tumor
suppressor genes including ATM which plays an import-
ant role in cell cycle regulation. The deletion of 17p is
detected at a frequency of 3–7 % at diagnosis [9, 30].
The 17p deletion often involves the entire p-arm, but
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codes the TP53 gene among several other genes. This gene
is a key regulator of the cell cycle. The 11q deletion was
found in 2 patients in stage C and 1 B stage while the 3
patients with 17p deletion were all in stage C. No signifi-
cance was found between these poor prognosis deletions
and Binet clinical stages (Table 4). This could be explained
by the small size of our series as Lai et al. [33] obtained
significant differences in the distribution of p53 deletion
according to Binet classification system (P = 0.008).
The number of lymphocytes count was significantly
greater in patients with stage C than in those in the
group with stages A or B (p = 0.005). A high lymphocy-
tosis could be associated to poor prognosis in African
with CLL. However Shvidel et al. [34] demonstrated that
although CLL patients presenting with hyperleukocytosis
at diagnosis generally have an aggressive clinical course,
this is not an independent predictor of survival in CLL.
In any case, further studies are needed to better define
the role of lymphocytosis in prognostic factors for CLL.
Conclusion
This study helps to define the characteristics of CLL in
sub-Saharan Africa. The patient type would be aged
60 years with a major tumor syndrome, higher lympho-
cytosis to 150 x 109/L, stage C according to Binet clin-
ical stage, positivity of CD38 and at least one cytogenetic
abnormality at biological level.
CLL is certainly much less common in Africa than in
Western countries but African patients seem to have a
worse prognosis compared to Westerners. We assess
time to treatment and the time of overall survival at
5 years to better answer this question.
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